We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-7.07%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$393M
AUM Growth
-$29.9M
(-7.1%)
Cap. Flow
+$15.9M
Cap. Flow
% of AUM
4.04%
Top 10 Holdings %
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8
Top Buys
| 1 |
Revolution Medicines
RVMD
|
+$5.71M |
| 2 |
TELA Bio
TELA
|
+$4.05M |
| 3 |
Keros Therapeutics
KROS
|
+$2.94M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$2.56M |
| 5 |
BCAX
Bicara Therapeutics
BCAX
|
+$2.2M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
+$3.48M |
| 2 |
SLRN
ACELYRIN
SLRN
|
+$2.49M |
| 3 |
Aquestive Therapeutics
AQST
|
+$2.13M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$1.3M |
| 5 |
Axogen
AXGN
|
+$1.26M |
Sector Composition
| 1 | Healthcare | 86.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $35.8M | 9.1% |
397,505
-4,000
| -1% | -$388K |
|
2
Stereotaxis
STXS
$160M
| $31.2M | 7.93% |
13,680,554
| – | – |
|
|
3
Revolution Medicines
RVMD
$39.3B
| $27.6M | 7.02% |
631,176
+113,182
| +22% | +$5.71M |
|
4
AtriCure
ATRC
$1.76B
| $19.6M | 4.98% |
641,673
| – | – |
|
|
MRUS
5
DELISTED
Merus
MRUS
| $19M | 4.83% |
451,804
+39,231
| +10% | +$1.88M |
|
6
Cytokinetics
CYTK
$11.2B
| $18.7M | 4.76% |
398,100
| – | – |
|
7
Ascendis Pharma A/S
ASND
$17.5B
| $14.2M | 3.62% |
103,355
+13,783
| +15% | +$1.81M |
|
|
8
Axogen
AXGN
$2.04B
| $14M | 3.55% |
846,882
-89,012
| -10% | -$1.26M |
|
9
iShares Biotechnology ETF
IBB
$9.23B
| $13.6M | 3.44% |
102,500
| – | – |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $13.1M | 3.32% |
149,763
+28,000
| +23% | +$2.56M |
|
11
IDEAYA Biosciences
IDYA
$3.54B
| $12.8M | 3.26% |
498,827
+27,417
| +6% | +$776K |
|
12
Xenon Pharmaceuticals
XENE
$6.53B
| $10.7M | 2.73% |
273,739
| – | – |
|
13
Neurocrine Biosciences
NBIX
$17.2B
| $9.78M | 2.48% |
71,615
+2,000
| +3% | +$247K |
|
|
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
| $9.27M | 2.36% |
731,363
-19,000
| -3% | -$264K |
|
15
Biohaven
BHVN
$2.25B
| $8.23M | 2.09% |
220,235
+33,105
| +18% | +$1.54M |
|
16
Tandem Diabetes Care
TNDM
$1.06B
| $8.04M | 2.04% |
223,208
+19,000
| +9% | +$643K |
|
17
Syndax Pharmaceuticals
SNDX
$2.08B
| $7.17M | 1.82% |
542,002
+15,300
| +3% | +$262K |
|
|
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
| $6.87M | 1.75% |
811,678
+88,000
| +12% | +$911K |
|
19
UroGen Pharma
URGN
$1.95B
| $5.25M | 1.33% |
492,515
+33,600
| +7% | +$402K |
|
20
DexCom
DXCM
$28.1B
| $5.1M | 1.3% |
65,552
| – | – |
|
21
BioCryst Pharmaceuticals
BCRX
$2.41B
| $5.02M | 1.28% |
667,000
| – | – |
|
|
22
Edgewise Therapeutics
EWTX
$4.37B
| $5M | 1.27% |
187,140
-40,766
| -18% | -$1.3M |
|
|
23
TELA Bio
TELA
$34.8M
| $4.35M | 1.11% |
+1,441,029
| New | +$4.05M |
|
24
ProQR Therapeutics
PRQR
$244M
| $4.15M | 1.06% |
1,567,561
+661,979
| +73% | +$2.1M |
|
25
Kura Oncology
KURA
$1B
| $3.91M | 0.99% |
448,368
+40,000
| +10% | +$576K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML